Logo
x

Search

Subscribe Now

Guardant Health

Guardant Health Receives MHLW Approval for Guardant360 CDx as Companion Diagnostic to Enhertu for Non-Small Cell Lung Cancer

Guardant Health Receives MHLW Approval for Guardant360 CDx as Companion Diagnostic to Enhertu for Non-Small Cell Lung Cancer

  • September 6, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Guardant Health Reports the Submission of Premarket Approval Application to the US FDA for Shield Blood Test to Detect Colorectal Cancer

Guardant Health Reports the Submission of Premarket Approval Application to the US FDA for Shield Blood Test to Detect Colorectal...

  • March 13, 2023
Guardant Health Collaborated with AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext for Taletrectinib 

Guardant Health Collaborated with AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext for Taletrectinib 

  • February 3, 2023
Guardant Health Receives the US FDA’s Approval of Guardant360 CDx Liquid Biopsy Test for Breast Cancer

Guardant Health Receives the US FDA’s Approval of Guardant360 CDx Liquid Biopsy Test for Breast Cancer

  • January 31, 2023
Guardant Health Reports the Availability of Guardant Reveal Liquid Biopsy Test for the Detection of Residual Disease and Recurrence of Early-Stage Breast and Lung Cancers

Guardant Health Reports the Availability of Guardant Reveal Liquid Biopsy Test for the Detection of Residual Disease and Recurrenc...

  • August 16, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.